PT-141 For ED

What do you do when Viagra no longer works like it used to?

Have you considered PT 141 (also known as Bremelanotide)?  This new medication has been FDA approved for women’s sexual dysfunction and will be called Vyleesi.  However, it is also effective in men.

BrandeisMD is one of the first medical practices in California to offer this brand new medication for ED!

What is PT-141?

PT-141 can work when Viagra does not.  It uses a different pathway than medications like Viagra.  PT-141 is an exciting new option in addressing erectile dysfunction with the further benefit of increased arousal and libido.  Also known as Bremelanotide, PT-141 is a melanocortin-stimulating protein that has proven beneficial in the treatment of mild-to-moderate erectile dysfunction [Diamond, et al. 2004].

Mechanism of Action

PT-141 binds to melanocortin receptors (MC3-R and MC4-R) in the hypothalamus in the brain.  [Molinoff et al. 2003]   Activation of these brain neurons has a direct erectogenic effect resulting in on-demand erections.  The potency of the medication can last hours.  The libido-enhancing effects of PT-141 typically last even longer.

Route of Administration

PT-141 is administered as a subcutaneous injection that can be easily injected into the abdomen.  The small dose also makes traveling with PT-141 relatively simple.  While the medicine is stable for long periods of time in a chilled environment, PT-141 is stable for 1 week at room temperature.

Side Effects

The most commonly occurring side effect is nausea.  Other, less common side effects include flushing and headache.  [Krapf, et al. 2016]  Previously, PT-141 was tested by intranasal administration; however, this had the side effect of elevating blood pressure.  By administering the medication through subcutaneous injection, the incidence of increased blood pressure dropped substantially.

Summary

PT-141 is currently FDA-approved for the treatment of female Hypoactive sexual desire disorder; however, current research has not yet caught up to its use in men.  The limited body of research has demonstrated increased arousal and spontaneous erections.  For more information or to discuss treatment involving PT-141, schedule an appointment with Dr. Brandeis today.

References

Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB.  Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.  International Journal of Impotence Research (2004)16,51-59

Molinoff PB, Shadiak AM, Earle DC, Diamond LE, Quon, CY.  PT-141: A Melanocortin Agonist for the Treatment of Sexual Dysfunction.  Annals of the New York Academy of Sciences (2003)994:96-102

Krapf, Jill M., John E. Buster, and Andrew T. Goldstein. Management of Hypoactive Sexual Desire Disorder (HSDD). Management of Sexual Dysfunction in Men and Women Springer New York, 2016. 233-249.